ASH 2016 | The genetics of multiple myeloma and how we can use it to improve outcomes
Gareth Morgan, MD, FRCP, FRCPath, PhD of the UAMS Myeloma Institute, Little Rock, AR discusses the genetics of multiple myeloma (MM) and how we can use it to improve outcomes. Prof. Morgan explains that it is becoming clear that multiple myeloma is not a single disease, but a collection of diseases that have similar features and should therefore be treated differently. He believes that it is extremely important to design technologies that will identify patients who will have poor outcomes.
Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up